Home › Funds › TCG Crossover Management, LLC › LBRX
TCG Crossover Management, LLC position in LBRX
LB PHARMACEUTICALS INC · Health Care
TCG Crossover Management, LLC reported holding 1,447,310 shares of LBRX (LB PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$47.0M, representing 1.13% of its reported portfolio and ranking #24 among its reported holdings. TCG Crossover Management, LLC has disclosed LBRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How TCG Crossover Management, LLC's LBRX position evolved
TCG Crossover Management, LLC first disclosed a stake in LBRX in Q3 2025 at 1,745,016 shares (US$27.6M). The position peaked in Q2 2026 at 1,447,310 shares, worth US$47.0M. Across 4 filings, TCG Crossover Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,447,310 shares valued at US$47.0M — a reduction of -392,179 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 1.75M | $27.55M | New |
| Q4 2025 | 1.75M | $38.84M | Hold |
| Q1 2026 | 1.84M | $45.28M | Add |
| Q2 2026 | 1.45M | $46.97M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 110 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$108.8M), RA CAPITAL MANAGEMENT, L.P. (US$71.7M), Trails Edge Capital Partners, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $108.82M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $71.68M · Q2 2026
- Trails Edge Capital Partners, LP 1.52M sh · $49.43M · Q2 2026
- Commodore Capital LP 1.50M sh · $48.68M · Q2 2026
- Caligan Partners LP 1.44M sh · $46.67M · Q2 2026
- Spruce Street Capital LP 1.38M sh · $44.66M · Q2 2026
- Nantahala Capital Management, LLC 1.05M sh · $34.17M · Q2 2026
- Vivo Capital, LLC 800.00K sh · $25.96M · Q2 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $20.47M · Q2 2026
- Logos Global Management LP 585.00K sh · $18.99M · Q2 2026
- GREAT POINT PARTNERS LLC 317.22K sh · $10.30M · Q2 2026
- HighVista Strategies LLC 211.51K sh · $6.86M · Q2 2026
More on TCG Crossover Management, LLC
FAQ
How long has TCG Crossover Management, LLC held LBRX?
TCG Crossover Management, LLC has disclosed LBRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is TCG Crossover Management, LLC's current position in LBRX?
As of Q2 2026, TCG Crossover Management, LLC holds 1.45M shares of LBRX (LB PHARMACEUTICALS INC), valued at $46.97M, representing 1.13% of its reported portfolio and ranking #24.
Has TCG Crossover Management, LLC been buying or selling LBRX?
In the latest 13F filing (Q2 2026), TCG Crossover Management, LLC reduced its position in LBRX. The position peaked in Q2 2026 at 1.45M shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Trails Edge Capital Partners, LP, among 110 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.